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Homocysteine and Small Vessel Stroke: A
Mendelian Randomization Analysis
Susanna C. Larsson, PhD ,1,2 Matthew Traylor, PhD ,3 and Hugh S. Markus, FMedSci3
Objective: Trials of B vitamin therapy to lower blood total homocysteine (tHcy) levels for prevention of stroke are
inconclusive. Secondary analyses of trial data and epidemiological studies suggest that tHcy levels may be particularly
associated with small vessel stroke (SVS). We assessed whether circulating tHcy and B vitamin levels are selectively
associated with SVS, but not other stroke subtypes, using Mendelian randomization.
Methods: We used summary statistics data for single-nucleotide polymorphisms (SNPs) associated with tHcy (n = 18),
folate (n = 3), vitamin B6 (n = 1), and vitamin B12 (n = 14) levels, and the corresponding data for stroke from the
MEGASTROKE consortium (n = 16,952 subtyped ischemic stroke cases and 404,630 noncases).
Results: Genetically predicted tHcy was associated with SVS, with an odds ratio of 1.34 (95% confidence interval [CI],
1.13–1.58; p = 6.7 × 10–4) per 1 standard deviation (SD) increase in genetically predicted tHcy levels, but was not asso-
ciated with large artery or cardioembolic stroke. The association was mainly driven by SNPs at or near the MTHFR and
MUT genes. The odds ratios of SVS per 1 SD increase in genetically predicted folate and vitamin B6 levels were 0.49
(95% CI, 0.34–0.71; p = 1.3 × 10–4) and 0.70 (95% CI, 0.52–0.94; p = 0.02), respectively. Genetically higher vitamin B12
levels were not associated with any stroke subtype.
Interpretation: These findings suggest that any effect of homocysteine-lowering treatment in preventing stroke will be
confined to the SVS subtype. Whether genetic variants at or near the MTHFR and MUT genes influence SVS risk
through pathways other than homocysteine levels and downstream effects require further investigation.
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The B vitamins folate, vitamin B6, and vitamin B12, play anessential role in the metabolism of homocysteine (Fig 1).
Insufficient levels of either of these vitamins can lead to
increased blood levels of total homocysteine (tHcy), which has
been epidemiologically linked to increased risk of cardiovascular
disease.1–4 However, the causality of the association has been
disputed because a number of randomized controlled trials
(RCTs) have failed to show a benefit of homocysteine-lowering
therapy with B vitamins on coronary heart disease, total cardio-
vascular disease, and all-cause mortality,2,5–7 although a recent
primary prevention trial reported a reduction in incidence of
ischemic stroke.8 Furthermore, recent meta-analyses have indi-
cated that B vitamin supplementation significantly reduces the
risk of any stroke by 10% compared to placebo.7,9
Most RCTs assessed the benefit of homocysteine-
lowering therapy on overall stroke only. Ischemic stroke can
be caused by multiple pathologies, which result in distinct
subtypes, the most common of which are large artery stroke
(LAS) attributed to atherosclerosis, cardioembolic stroke
(CES), and small vessel stroke (SVS). If the association with
homocysteine is specific to one particular subtype, then fail-
ure to examine treatment effects on specific subtypes could
have resulted in diluted or null results, despite treatment
benefits for that subtype.
Several lines of evidence suggest that homocysteine
may be more strongly associated with the SVS subtype.
A secondary analysis of the largest trial of homocysteine-
lowering therapy in patients with stroke or transient ischemic
attack, VITATOPS (The VITAmins TO Prevent Stroke),
showed a marginally significant treatment effect for SVS, but
not other stroke subtypes.10 A magnetic resonance imaging
(MRI) substudy embedded in the same trial showed that
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homocysteine-lowering therapy significantly reduced the pro-
gression of white matter hyperintensities (an MRI marker of
small vessel disease).11 Although it did not reduce cognitive
decline in the same study,12 this may be because cognitive
testing has been shown to be insensitive to detect changes over
a 2- to 3-year period in this cerebral small vessel disease.13,14
Furthermore, several case-control studies have shown that ele-
vated tHcy levels are a stronger risk factor for SVS than other
ischemic stroke subtypes15–17 and that tHcy levels are higher
in patients with cerebral small vessel disease than in healthy
controls,18 although such studies only show associations and
cannot exclude confounding.
Mendelian randomization (MR) is an increasingly used
technique that can infer causality between exposure and
disease through the use of genetic variants, usually single-
nucleotide polymorphisms (SNPs), associated with the expo-
sure as proxies for the exposure.19,20 Use of genetic variants,
which are randomly allocated at conception, avoids reverse
causality and minimizes confounding by environmental fac-
tors in a similar manner as in an RCT.
Here, we used the MR design to determine whether
tHcy, folate, vitamin B6, and vitamin B12 levels are associated
with ischemic stroke, and whether any association is selective
to the SVS subtype, in a sample of 34,217 ischemic stroke
cases (including 16,952 subtyped cases) and 404,630 non-
cases. We also evaluated whether there were associations with
coronary artery disease (CAD), which shares pathogenesis
with LAS.
Materials and Methods
Data Sources
Summary statistics data for stroke were available from the MEGA-
STROKE consortium (http://megastroke.org/).21 We restricted
the analyses to studies comprising European-descent individuals to
minimize potential bias caused by population stratification. The
ischemic stroke data set included 404,630 noncases and 34,217
cases subtyped into SVS (n = 5,386), LAS (n = 4,373), and CES
(n = 7,193). Nonsubtyped ischemic stroke cases (n = 17,265)
were excluded from the subtype-specific analyses. Ischemic stroke
subtyping had been performed using the Trial of Org 10172 in
Acute Stroke Treatment criteria.22
Summary statistics data for CADwere available from the CAR-
DIoGRAMplusC4D consortium’s 1000 Genomes–based genome-
wide association meta-analysis of 48 studies, including 60,801 CAD
cases and 123,504 noncases (http://www.cardiogramplusc4d.org/).23
CAD included myocardial infarction (~70% of the total number of
cases), acute coronary syndrome, chronic stable angina, or coronary
artery stenosis of at least 50%.23
Studies contributing data to the MEGASTROKE and
CARDIoGRAMplusC4D consortia received ethical approval from
relevant institutional review boards. In the present study, we only
used summarized (ie, aggregated) data from these two consortia.
Selection of SNPs
We selected all SNPs associated with circulating levels of tHcy,
folate, vitamin B6, or vitamin B12 at genome-wide significance
threshold (p < 5 × 10–8) in the hitherto largest genome-wide
association meta-analyses on tHcy (n = 44,147 individuals)24 and
the B vitamins (n = 37,465 individuals for folate25; n = 1,864
FIGURE 1: Simplified overview of the role of folate, vitamin B6, and vitamin B12 in homocysteine metabolism. In the remethylation
pathway, homocysteine is reconverted to methionine by receiving a methyl group from 5-methyltetrahydrofolate, the active form
of folate, or betaine. Irreversible removal of homocysteine occurs through the transsulphuration pathway in which homocysteine
condenses with serine to form cystathionine. B6 = vitamin B6; B12 = vitamin B12; BHMT = betaine homocysteine methyltransferase;
CBS = cystathionine-β-synthase; CTH = cystathionine-gamma-ligase; DH = dihydro; DMG = dimehtylglycine; Hcy = homocysteine;
Met = methionine; MS = methionine synthase (encoded by the MTR gene); MTHFR = methylenetetrahydrofolate reductase; TH =
tetrahydro.
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individuals for vitamin B6
26; and n = 45,576 individuals for vita-
min B12
25) in individuals of European ancestry. Where the speci-
fied SNP was unavailable in the stroke or CAD data set, we used a
proxy SNP in linkage disequilibrium (r2 > 0.9) with the specified
SNP. For one SNP (rs7788053) associated with vitamin B12, no
proxy was found. Hence, our analyses included 18 SNPs for tHcy,
three for folate, one for vitamin B6, and 14 for vitamin B12
(Supplementary Table 1). We verified that the SNPs within each
exposure were independent (R2 < 0.1 in 1000G CEU popula-
tion). Across the four exposures, two folate-associated SNPs and
four vitamin B12–associated SNPs were in linkage disequilibrium
with an tHcy-associated SNP (Supplementary Table 1). The SNP
associated with vitamin B6 was not in in linkage disequilibrium
with any of the SNPs for the other three exposures.
Characteristics of the tHcy- and B vitamin–associated SNPs
and their associations with SVS are shown in Supplementary
Table 1. Variance in exposure explained by the SNPs has been
estimated to be 4.6% to 5.9% for tHcy,24 1.0% for folate,25 and
6.3% for vitamin B12.
25 The B6-associated SNP was estimated to
explain 1.3% of the variance in vitamin B6 levels.
Statistical Analysis
The primary analyses were conducted using the inverse-variance
weighted method.27 Where a significant association was observed, we
performed sensitivity analyses using the weighted median and MR-
Egger methods.27 The MR-PRESSO method was used to identify
potential outliers.28 In a further sensitivity analysis of tHcy, we
included only the lead SNP of each of the 13 tHcy-associated loci.
All results are reported per an approximate 1 standard
deviation (SD) increment of each exposure. We prespecified a
Bonferroni-corrected significance threshold of α = 0.0025 (where
α = 0.05/20 [four exposures and five outcomes]) to adjust for mul-
tiple testing. Associations with p values between 0.05 and 0.0025
were considered suggestive evidence of a possible association. The
statistical analyses were conducted using Stata (StataCorp LP,
College Station, TX) and the MendelianRandomization package29
for R (R Foundation for Statistical Computing, Vienna, Austria).
Assessment of Pleiotropy
We assessed whether the tHcy-associated SNPs were associated
with potential confounders or macronutrient intake by searching
the PhenoScanner database.30 We looked up associations with the
following established or possible risk factors for SVS: systolic and
diastolic blood pressure,31 high-density lipoprotein cholesterol,32
type 2 diabetes mellitus,33 and smoking.31
Results
Genetically higher tHcy was associated with higher odds of
SVS, but not associated with either LAS or CES (Fig 2). The
odds ratio (OR) of SVS per 1 SD increase in genetically pre-
dicted tHcy levels was 1.34 (95% confidence interval [CI],
1.13–1.58; p = 6.7 × 10–4; Figs 2 and 3). There was sug-
gestive evidence of a possible association between genetically
predicted tHcy levels and all ischemic stroke (p = 0.02), but
no association with CAD (p = 0.61; Fig 2).
Results for tHcy levels and SVS were similar in sensi-
tivity analyses using the weighted median and MR-Egger
methods, although with less-precise estimates (Supplemen-
tary Table 2). There was no indication of directional pleiot-
ropy (MR-egger intercept, –0.001; 95% CI –0.039 to
0.037; p = 0.96). In the MR-PRESSO outlier test, the SNP
near the MUT gene was found to be a possible outlier, but
the association between tHcy and SVS remained after exclu-
sion of this SNP (Supplementary Table 2). Likewise, the
association persisted (Supplementary Table 2) after omission
of SNPs associated with one or more potential SVS risk fac-
tors or macronutrient intake (Supplementary Table 3). The
results were also consistent when restricting the analysis to
the lead SNP of each of the 13 tHcy-associated loci (OR,
1.31; 95% CI, 1.08–1.58; p = 0.005). However, the associa-
tion did not remain in a post-hoc analysis excluding the out-
lying SNP near the MUT gene along with the two SNPs at
or near the MTHFR gene (OR, 1.08; 95% CI, 0.87–1.34;
p = 0.47). The SNP, rs1801133, in MTHFR explains most
of the variance in tHcy levels and is also strongly associated
with folate levels (Supplementary Table 1).
Genetically predicted folate and vitamin B6, but not
vitamin B12, levels were inversely associated with SVS, but
the association with vitamin B6 levels did not reach signifi-
cance at the Bonferroni-corrected threshold (Fig 2). In con-
trast, folate, vitamin B6, and vitamin B12 levels were not
associated with LAS, CES, all ischemic stroke, or CAD
(Fig 2). The OR of SVS per 1 SD increment in genetically
predicted folate and vitamin B6 levels were 0.49 (95% CI,
0.34–0.71, p = 1.3 × 10–4) and 0.70 (95% CI, 0.52–0.94,
p = 0.02), respectively. The results for folate were consistent
when restricting the analysis to the lead SNP of each of the
two folate-associated loci (OR, 0.52; 95% CI, 0.33–0.83;
p = 5.3 × 10–3). Weighted median and MR-Egger analyses
could not be performed with only three SNPs for folate and
one SNP for vitamin B6. Among the folate-associated SNPs,
rs1801133 was associated with systolic and diastolic blood
pressure (Supplementary Table 3). The vitamin B6–associated
SNP was not associated with possible SVS risk factors
(at p values <0.01).
Discussion
This study showed an overall significant positive association
of genetically predicted tHcy levels and an inverse associa-
tion of genetically predicted folate levels with SVS. More-
over, the association was specific to this subtype and was
not present for the other major ischemic stroke subtypes,
that is, LAS and CES. We also observed no association
between genetically higher tHcy and CAD, consistent with
previous studies24,34 and with the lack of association with
LAS in which atherosclerosis also plays a key role. Our
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findings support those from subgroup analyses within
VITATOPS10 and the MRI substudy within that trial,11
which both suggested a specific treatment effect in the
SVS subtype.
Increasing data have implicated endothelial damage
as a key process in the pathogenesis of small vessel disease.35
Experimental studies have shown that elevated tHcy levels
can lead to alterations within the blood vessel wall.36,37 The
main mechanisms responsible for these modifications
include direct endothelial damage attributed to increased
oxidative stress and proinflammatory effects.37–42 Experi-
mental studies in animals and humans indicate that oxi-
dative or nitrosative stress play a role in reducing the
bioavailability of nitric oxide and augmenting endothelial
dysfunction caused by hyperhomocysteinemia.36,37,39,42
Oxidative stress, which may be induced by hyperhomo-
cysteinemia, causes impaired cerebral vascular function by
disrupting endothelium-dependent nitric oxide signaling.43
Cerebral microvessels appears to be more sensitive to hyper-
homocysteinemia than extracranial blood vessels,36 support-
ing a more prominent role of elevated tHcy levels in SVS
than other ischemic stroke subtypes as well as coronary heart
disease, for which no benefit of homocysteine-lowering treat-
ment has been observed.2,5–7
Previous MR studies of tHcy in relation to stroke
have yielded conflicting results. In one study, rs1801133
in the MTHFR gene, encoding the key enzyme in homo-
cysteine metabolism (Fig 1), which is strongly associated
with tHcy24 and folate25 levels, was associated with SVS
(n = 1,359 cases), but not with other stroke subtypes.44
However, another study found no association of a genetic
risk score consisting of 18 tHcy-associated SNPs with
either SVS (n = 1,894 cases) or other subtypes.45 We used
data from a much larger stroke cohort and also assessed
FIGURE 2: Associations of genetically predicted tHcy, folate, vitamin B6, and vitamin B12 levels with ischemic stroke subtypes, all
ischemic stroke, and coronary artery disease. The odds ratios (OR) are per genetically predicted 1 SD increase in each exposure.
AIS = all ischemic stroke; B6 = vitamin B6; B12 = vitamin B12; CAD = coronary artery disease; CES = cardioembolic stroke;
CI = confidence interval; LAS = large artery stroke; OR = odds ratio; SVS = small vessel stroke; tHcy = total homocysteine.
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associations with homocysteine-lowering B vitamins, which
were not done in earlier studies.
A recent meta-analysis of RCTs showed that vitamin
B therapy may only reduce stroke risk in individuals with
normal renal function,9 which is closely associated with
cerebral small vessel disease.46 In this MR study, we were
unable to examine whether genetically predicted tHcy and
the B vitamin levels were more strongly associated with
SVS in individuals with normal renal function, but this
warrants investigation in future studies.
The reason for the lack of association between genet-
ically higher vitamin B12 levels and SVS is unclear, but a
possible explanation is that vitamin B12 levels have little
impact on tHcy levels. In a meta-analysis of RCTs, folic
acid (synthetic form of folate) supplementation reduced
tHcy levels by 25% (95% CI, 23–28) and vitamin B12
supplementation produced an additional 7% (95% CI,
3–10) lowering of tHcy levels.47
A major strength of this study is the MR design. Like
RCTs, MR studies avoid reverse causality and minimize con-
founding by environmental factors. However, unlike RCTs,
which usually evaluate the effect of short-term treatment,
results from MR studies can be reflective of life-long expo-
sure as genetic variants are fixed at conception. Another
important strength is the possibility to examine the associa-
tion between tHcy and B vitamin levels with SVS in a large
sample of over 5,000 SVS cases. RCTs of B vitamin therapy
for stroke prevention have only included a few hundred cases
(up to approximately 700 cases of any stroke) and did not
examine the benefit on specific ischemic stroke subtypes. An
additional strength of this study is that most SNPs used as
proxies for tHcy and B vitamin levels are located in genes
with known functions related to homocysteine, folate, and
vitamin B12 pathways.
24,25 The SNP associated with vitamin
B6 levels is located near the ALPL gene, encoding tissue-
nonspecific alkaline phosphatase, which likely is involved in
the catabolism of vitamin B6.
26
A limitation is that we only had three SNPs as
instrumental variables for folate levels and one SNP for
vitamin B6 levels. This resulted in low statistical power in
the analyses of these B vitamins. In addition, with only
one or three SNPs, sensitivity analyses to explore pleiot-
ropy could not be conducted.
A potential threat to the reliability of the results
from an MR analysis is pleiotropy, which occurs when a
genetic variant affects more than one phenotype. Our sen-
sitivity analyses based on the weighted median, MR-Egger,
and MR-PRESSO methods provided no evidence that
pleiotropy explained the observed association between
tHcy levels and SVS. Nevertheless, the association did not
remain in a post-hoc analysis omitting the three SNPs at
or near the MTHFR and MUT loci of which MTHFR is
the key gene involved in folate metabolism and also
strongly associated with folate levels. Hence, we cannot
rule out that the observed association between tHcy levels and
SVS is driven by other effects of folate, not mediated through
tHcy levels, or other pleiotropic pathways affecting the risk of
SVS, but not LAS, CES, or CAD. However, the major SVS
FIGURE 3: Association of genetically predicted tHcy levels with small vessel stroke. The odds ratios (OR) are per genetically
predicted 1 SD increase in tHcy. CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism; SVS = small
vessel stroke; tHcy = total homocysteine. *p for the association between the SNP and tHcy; †p for the association between the
SNP and SVS.
5
Larsson et al.: Homocysteine and Small Vessel Stroke
risk factors, such as blood pressure,31 high-density lipoprotein
cholesterol,32 type 2 diabetes mellitus,33 and smoking,31 are
also associated with the other stroke subtypes and CAD. Some
of those cardiovascular risk factors may influence tHcy levels
or mediate the potential adverse effect of higher tHcy levels on
SVS. Smokers have higher tHcy levels and lower folate, vita-
min B6, and vitamin B12 levels compared to never smokers.
48
Furthermore, raised tHcy levels may cause an increase in
blood pressure mediated by damage to vascular smooth mus-
cle and endothelial cells, which, in turn, could lead to a loss of
arterial vasodilation and vascular integrity.36–42,49 Blood pres-
sure may thus be in the causal pathway linking elevated tHcy
levels to SVS risk. A previous study showed that rs1801133 in
theMTHFR gene, which is strongly associated with tHcy and
folate levels, was significantly associated with small vessel
stroke in hypertensive individuals, but not in normotensive
individuals.44 This gene-environment interaction provides evi-
dence that the association between genetically predicted tHcy
levels and SVS is a result of tHcy, because if the association
were a result of directional pleiotropy, then it would likely to
be present in both hypertensive and normotensive individuals.
Moreover, one of the largest RCTs on homocysteine-lowering
treatment for stroke prevention showed that folic acid supple-
mentation significantly reduced the risk of stroke in hyperten-
sive individuals.8
Another possible source of bias in an MR study is pop-
ulation stratification. We reduced this possible bias by
restricting the study populations to individuals of European
ancestry. A further shortcoming is that six of the ten studies
included in the genome-wide association meta-analysis of
tHcy were included in MEGASTROKE. This could lead to
model overfitting and bias in the direction of the observa-
tional association between tHcy and SVS. However, if genetic
associations with tHcy levels were estimated in noncases, then
sample overlap would not result in bias or type 1 error infla-
tion.50 The genome-wide association meta-analyses of folate,
vitamin B6, and vitamin B12 did not include studies that were
part of MEGASTROKE.
In conclusion, our results provide support for possible
associations of tHcy and folate levels with SVS and that these
relationships are specific for the SVS subtype. This suggests
that any effect of folic acid supplementation in preventing
stroke will be limited to the SVS subtype. Whether genetic
variants at or near the MTHFR and MUT genes influence
the risk of SVS through pathways other than tHcy levels and
downstream effects require further investigation.
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